Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
66 hedge funds and large institutions have $248M invested in Eiger BioPharmaceuticals, Inc. in 2014 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 9 closing their positions.
233% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 9
102% more capital invested
Capital invested by funds: $123M → $248M (+$125M)
47% more funds holding
Funds holding: 45 → 66 (+21)
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$7.55M |
| 2 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$5.03M |
| 3 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$3.87M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.53M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$4.7M |
| 2 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$3.44M |
| 3 |
VAM
Visium Asset Management
New York
|
-$3.34M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$1.62M |
| 5 |
Axa
Paris,
France
|
-$1.18M |
EIGR Hedge Fund Activity: Q4 2014 in Review
66 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q4 2014, worth a combined $248M — up 102% from $123M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new EIGR positions and 9 closed out — a net gain of 21 holders — while 14 added to existing stakes and 11 trimmed.
The largest buyer was Eagle Asset Management, adding an estimated $7.55M. The largest seller was Tekla Capital Management, cutting an estimated $4.7M.
- 66 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q4 2014, up from 45 in Q3 2014.
- Funds reported $248M of Eiger BioPharmaceuticals, Inc. stock for Q4 2014, up 102% quarter-over-quarter.
- 30 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q4 2014 and 9 closed out, a net change of +21 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q4 2014 was Eagle Asset Management, an estimated $7.55M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q4 2014 was Tekla Capital Management, an estimated $4.7M sold.
Based on aggregated 13F filings for Q4 2014.